2 weeks Ago By ABMN Staff
Renaissance Technologies LLC lifted its stake in shares of Atea Pharmaceuticals, Inc. ( NASDAQ:AVIR – Free Report ) by 0.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission.
The fund owned 1,216,600 shares of the company’s stock after buying an additional 9,500 shares during the period. Renaissance Technologies LLC owned about 1.44% of Atea Pharmaceuticals worth $4,076,000 at the end of the most recent quarter.
Several other institutional investors have also bought and sold shares of AVIR. BML Capital Management LLC grew its stake in shares of Atea Pharmaceuticals by 14.4% in the 4th quarter.
BML Capital Management LLC now owns 7,608,312 shares of the company’s stock worth $25,488,000 after acquiring an additional 958,312 shares in the last quarter. State Street Corp increased its stake in Atea Pharmaceuticals by 0.7% in the 3rd quarter.
State Street Corp now owns 1,733,486 shares of the company’s stock valued at $5,807,000 after buying an additional 11,566 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in Atea Pharmaceuticals by 1.
4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 659,527 shares of the company’s stock valued at $2,209,000 after buying an additional 9,370 shares during the last quarter.
Federated Hermes Inc. lifted its position in shares of Atea Pharmaceuticals by 1.9% during the 4th quarter.
Federated Hermes Inc. now owns 582,939 shares of the company’s stock worth $1,953,000 after buying an additional 10,856 shares in the last quarter. Finally, JPMorgan Chase & Co.
boosted its stake in shares of Atea Pharmaceuticals by 329.7% in the 4th quarter. JPMorgan Chase & Co.
now owns 409,259 shares of the company’s stock worth $1,371,000 after buying an additional 314,015 shares during the last quarter. Institutional investors own 86.67% of the company’s stock.
Atea Pharmaceuticals Price Performance Shares of NASDAQ AVIR opened at $2.86 on Tuesday. The business’s fifty day moving average price is $2.
99 and its 200-day moving average price is $3.18. Atea Pharmaceuticals, Inc.
has a one year low of $2.60 and a one year high of $4.15.
The stock has a market capitalization of $244.60 million, a PE ratio of -1.38 and a beta of 0.
17. Wall Street Analysts Forecast Growth A number of analysts recently commented on the company. William Blair reiterated an “outperform” rating on shares of Atea Pharmaceuticals in a report on Friday, March 7th.
Morgan Stanley decreased their price objective on shares of Atea Pharmaceuticals from $6.20 to $6.00 and set an “equal weight” rating for the company in a report on Friday, April 11th.
Get Our Latest Stock Report on AVIR Atea Pharmaceuticals Company Profile ( Free Report ) Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. Featured Stories Receive News & Ratings for Atea Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atea Pharmaceuticals and related companies with MarketBeat.
com's FREE daily email newsletter ..
